Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lisata Therapeutics (LSTA) Return on Sales (2016 - 2025)

Lisata Therapeutics filings provide 12 years of Return on Sales readings, the most recent being 22.72% for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales fell 1811.0% year-over-year to 22.72%, compared with a TTM value of 82.93% through Dec 2025, down 6295.0%, and an annual FY2025 reading of 82.93%, down 6295.0% over the prior year.
  • Return on Sales hit 22.72% in Q4 2025 for Lisata Therapeutics, down from 17.05% in the prior quarter.
  • The five-year high for Return on Sales was 4.61% in Q4 2024, with the low at 66.56% in Q2 2025.